Models for assessing anti-angiogenesis agents: Appraisal of current techniques

dc.contributor.authorMousa, Shaker A.
dc.contributor.authorDavis, Paul J.
dc.contributor.buuauthorYalçın, Murat
dc.contributor.departmentUludağ Üniversitesi/Veteriner Fakültesi/Fizyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-5600-8162tr_TR
dc.contributor.researcheridAAG-6956-2021tr_TR
dc.contributor.scopusid57192959734tr_TR
dc.date.accessioned2023-01-13T11:30:30Z
dc.date.available2023-01-13T11:30:30Z
dc.date.issued2017
dc.description.abstractA number of reproducible, technically satisfactory methods are available for experimentally measuring the anti- and proangiogenic activities of vascular growth factors, hormones, peptides, and pharmaceuticals. A group of widely used in vitro and in vivo assays for angiogenesis are reviewed here. The in vitro assays are the aortic ring, sprouting, and tube formation systems and the in vivo assays are the chick chorioallantoic membrane (CAM), the zebrafish, tumor xenografts in the immunocompromised mouse, and the Matrigel plug models. Human angiogenesis cannot be entirely reproduced in a single assay system. Thus, satisfactory preclinical anti- and proangiogenesis assay results do not assure clinical efficacy. Most of the assays discussed here, however, respond predictably to standard angiogenesis inhibitors and proangiogenesis factors and are cost effective.en_US
dc.identifier.citationMousa, S. A. vd. (2017). ''Models for assessing anti-angiogenesis agents: Appraisal of current techniques''. ed. Mousa, S. A. ve Davis, P. J. Anti-Angiogenesis Strategies in Cancer Therapies, 21-38.en_US
dc.identifier.endpage38tr_TR
dc.identifier.scopus2-s2.0-85054477973tr_TR
dc.identifier.startpage21tr_TR
dc.identifier.urihttps://doi.org/10.1016/B978-0-12-802576-5.00002-4
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/B9780128025765000024
dc.identifier.urihttp://hdl.handle.net/11452/30454
dc.identifier.wos000422780700003tr_TR
dc.indexed.scopusScopusen_US
dc.indexed.wosBKCISen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalAnti-Angiogenesis Strategies in Cancer Therapiesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectActivated protein-kinaseen_US
dc.subjectIn-vivo angiogenesisen_US
dc.subjectThyroid-hormoneen_US
dc.subjectTetraiodothyroacetic aciden_US
dc.subjectCapillary formationen_US
dc.subjectTumor angiogenesisen_US
dc.subjectBasement-membraneen_US
dc.subjectCell interfaceen_US
dc.subjectChick-embryoen_US
dc.subjectVitroen_US
dc.subjectAngiogenesisen_US
dc.subjectAnti-angiogenesisen_US
dc.subjectAortic ringen_US
dc.subjectChick chorioallantoic membraneen_US
dc.subjectMatrigel plug assayen_US
dc.subjectSprouting assayen_US
dc.subjectTube formation assayen_US
dc.subjectXenograften_US
dc.subjectZebrafishen_US
dc.subject.scopusIntegrin; Thyroid Hormones; Nano-Diamino-Tetracen_US
dc.subject.wosOncologyen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.titleModels for assessing anti-angiogenesis agents: Appraisal of current techniquesen_US
dc.typeArticle
dc.typeBook Chapter

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: